Cancer imaging and clinical genetic testing coverage requirements provided.
Summary
HF703 would require Minnesota health plans to cover certain cancer-related imaging and clinical genetic testing when those services are recommended under evidence-based guidelines. The bill defines “clinical genetic testing” as germline multigene testing for inherited cancer risk and defines “imaging” by reference to the most recent National Comprehensive Cancer Network (NCCN) clinical practice guidelines. Coverage would apply to enrollees with an increased risk of cancer, as determined by NCCN, and to enrollees with a personal or family history of cancer when a health care provider recommends genetic testing for an inherited mutation.
The bill also specifies that this coverage generally must be provided without cost-sharing, including deductibles, copayments, and coinsurance. However, if applying the no-cost-sharing requirement before the deductible would make a health plan incompatible with federal rules for health savings accounts or catastrophic plans, then cost-sharing may still apply until the deductible is met. The bill takes effect January 1, 2026, and applies to health plans offered, issued, or renewed on or after that date.
Impact
HF703 would amend Minnesota Statutes chapter 62Q by adding a new section requiring health plan coverage for specified cancer imaging and clinical genetic testing. It would expand mandated benefits in the commercial health insurance market and affect insurers, health plan administrators, and enrollees who meet the bill’s risk-based criteria. The bill also creates an exception to preserve compliance with federal HSA-qualified and catastrophic plan requirements, limiting the no-cost-sharing mandate in those cases.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available record. Based on the bill text and caption, the measure appears to be a patient-access and preventive-care bill aimed at reducing barriers to early cancer detection and hereditary cancer risk assessment. The absence of recorded opposition or amendments in the provided materials suggests the bill’s sentiment cannot be fully assessed from the available context.
Contention
The main policy tension in HF703 is between expanding access to cancer screening and genetic testing and preserving plan design flexibility, especially for high-deductible health plans, HSA-qualified coverage, and catastrophic plans. Another likely point of discussion is the use of NCCN guidelines as the standard for determining eligibility, since tying coverage to external clinical guidelines can raise questions about cost, scope, and administrative implementation. No specific legislators, stakeholders, or objections are identified in the provided materials.